item management s discussion and analysis of financial condition and results of operations overview since commencement of operations in  calypte biomedical corporation has reported its results as a development stage company  engaged in research  development and commercialization of its products 
the company s efforts have been primarily focused on developing and obtaining approval for its urine based diagnostic tests for sexually transmitted diseases 
in august  the company received a product license and an establishment license from the fda to manufacture and sell in interstate and foreign commerce the company s urine based hiv screening test for use in professional laboratory settings 
in october  calypte received notification that the fda will require additional data before it will approve an amendment to cambridge biotech corporation s product license application for its hiv western blot kit to allow use of the western blot kit as a confirmatory test with calypte s hiv urine screening assay 
in september  the company received official notice from the fda that the agency had completed its review of the cambridge biotech urine confirmatory test 
the review complete letter indicated that the application is approvable pending the completion of product labeling 
there can be no assurance that calypte will have significant revenues from sales of the hiv urine screening assay or the confirmatory test  if approved 
the company has a limited history of operations  and since its inception in february  the company has experienced significant operating losses 
as of december   the company had an accumulated deficit of million 
the company expects operating losses to continue as it initiates marketing and sales activities and expands research and development 
the company s marketing strategy is to use distributors  focused direct selling and marketing partners to penetrate certain targeted domestic markets 
the company plans to maintain a small direct sales force to sell the company s urine based hiv test to laboratories serving the life insurance  military  immigration and criminal justice markets 
international and other us markets will be addressed utilizing diagnostic product distributors 
the company does not have experience in manufacturing  marketing or selling its products in commercial quantities 
there can be no assurance that the company s products will be successfully commercialized or that the company will achieve significant product revenues 
in addition  there can be no assurance that the company will achieve or sustain profitability in the future 
results of operations years ended december  and product sales from calypte s hiv screening test increased  to  for the year ended december  from  for the year ended december  product costs increased million to million in from million in product sold in and relate to sales made primarily to laboratories for research and evaluation purposes 
sales in increased due to the company receiving more orders from these customers 
the company does not anticipate commencing significant sales for commercial uses until fda approval for the confirmatory test for calypte s hiv urine screening test is received 
since fda approval of calypte s hiv urine screening test in august  manufacturing costs related to the test have been included in product costs  rather than research and development expense 
the increase in product costs in reflects the inclusion of a full year of these costs compared to only a partial year in research and development expense decreased to million for the year ended december  from million for the year ended december  the decrease was principally due to the october reduction in workforce  the conscious effort to reduce costs and the recognition of certain product costs and inventory as separate financial statement items following fda approval of the company s hiv screening test in august selling  general and administrative expenses decreased to million for the year ended december  from million for the year ended december  the decrease was primarily due to the october reduction in workforce and the conscious effort to reduce costs 
in addition  included relocation costs which were not incurred in interest income expense and other income increased  to  for from  in the increase was primarily due to the company having interest expense on notes payable outstanding in  which were repaid in late  and interest earned from initial public offering and private placement proceeds in years ended december  and product sales from calypte s hiv screening test totaled  in the hiv screening test margin was negative during the year due to the overhead expense incurred in relation to the number of units produced 
research and development expense increased to million for the year ended december  from million for the year ended december  the increase was principally due to additional personnel  facility and material costs required for increased research and product development activity partially offset by the recognition of certain product costs and inventory as separate financial statement items following fda approval of the company s hiv screening test 
purchased in process research and development costs of million were incurred in  no such costs were incurred in the costs were attributable solely to the company s investment in pepgen corporation and the resulting write off of research and development in process acquired 
pepgen corporation is a research and development company engaged primarily in the development of therapeutic compounds 
selling  general and administrative expenses increased to million for the year ended december  from million for the year ended december  the increase was primarily due to personnel additions prior to the october reduction in workforce  relocation costs and other related expenses 
interest income expense and other income decreased  to  for from  in this decrease was primarily due to interest on notes payable outstanding during partially offset by interest income earned from initial public offering ipo proceeds 
liquidity and capital resources financing activities the company has financed operations from inception primarily through the private placement of preferred stock and common stock  the company s initial public offering ipo of common stock and  to a lesser extent  from payments related to research and development agreements  a bank line of credit  equipment lease financings and borrowings from notes payable 
since inception through december   the company has received approximately million in net proceeds from private placements of the company s equity securities and million in net proceeds in its ipo 
in addition  approximately million was borrowed by the company through equipment lease financings  of which approximately  was outstanding as of december   and million was received from research and development agreements 
during  the company completed its ipo of  shares of its common stock at per share 
after deducting underwriters discounts and commissions and additional expenses associated with the ipo  the company received net proceeds of million 
part of the proceeds was used to pay down a million bank line of credit  a  note payable to a former related party and the pepgen note payable of million 
the pepgen note payable was paid in october in october  the company entered into an equipment lease line of credit for million expiring on december  lease payments under the line of credit are based on the total delivered equipment cost multiplied by a monthly note factor of approximately approximate effective interest rate of 
in december  there was a drawdown of  on this equipment lease line of credit 
in april  the company entered into a line of credit agreement with a bank to borrow up to million at an interest rate of prime plus 
the agreement required the company to maintain certain financial covenants and comply with certain reporting and other requirements 
in addition  borrowings under the line of credit agreement were secured by the company s assets 
in june  the company drew down  on the line of credit 
subsequently  in july  the company drew down an additional  on the line of credit  thereby increasing the note payable to million 
the million was repaid in september and the line of credit was terminated 
in october  the company completed a private placement of  shares of its common stock at per share 
the company received proceeds of approximately million after deducting placement agent commissions and additional expenses associated with the private placement 
although the company believes current cash will be sufficient to meet the company s operating expenses and capital requirements for at least the next twelve months  the company s future liquidity and capital requirements will depend on numerous factors  including regulatory actions by the fda and other international regulatory bodies  market acceptance of its products  and intellectual property protection 
there can be no assurance that the company s products will be successfully commercialized or that the company will achieve significant product revenues 
in addition  there can be no assurance that the company will achieve or sustain profitability in the future 
there can be no assurance that the company will not be required to raise additional capital or that such capital will be available on acceptable terms  if at all 
operating activities for the years ended december  and  the company s cash used in operations was million and million  respectively 
the cash used in operations was primarily to fund research and development as well as manufacturing expenses related to the urine based hiv test along with selling  general and administrative expenses of the company 
in october  the company implemented an expense reduction program  including a significant reduction in its workforce 
employee termination costs associated with the expense reduction program were not material 
new accounting standards in june  the financial accounting standards board issued statement of financial accounting standards nos 
and  reporting comprehensive income sfas no 
and disclosures about segments of an enterprise and related information sfas no 
 respectively collectively  the statements 
the statements are effective for fiscal years beginning after december  sfas no 
establishes standards for reporting of comprehensive income and its components in annual financial statements 
sfas no 
established standards for reporting financial and descriptive information about an enterprise s operating segments in its annual financial statements and selected segment information in interim financial reports 
reclassification or restatement of comparative financial statements or financial information for earlier periods is required upon adoption of sfas no 
and sfas no 
 respectively 
application of the statements disclosure requirements will have no impact on the company s consolidated financial position or results of operations as currently reported 
year the company is reviewing its internal computer systems to ensure these systems are adequately able to address the issues expected to arise in connection with the upcoming year if necessary  the company expects to implement the systems necessary to address year issues and is reviewing the cost of such actions  if any 
the company expects such modifications to its internal systems  if necessary  will be made on a timely basis  and presently believes that  with modifications to existing software or converting to new software  if necessary  the year problem will not pose significant operational problems for the company s computer systems  however  there can be no assurance there will not be a delay in  or increased costs associated with  the implementation of such changes  if necessary  and the company s inability to implement such changes could have an adverse effect on future results of operations 
the company has not fully determined the extent to which the company may be impacted by third parties systems  which may not be year compliant 
the year computer issue may create risk for the company from third parties with whom the company deals 
there can be no assurance that the systems of other companies which the company deals with will be timely converted  or that any such failure to convert by another company could not have an adverse effect on the company 
item a 
quantitative and qualitative disclosures about market risk not applicable 

